Core Viewpoint - The article highlights the significant benefits of Semaglutide for patients with type 2 diabetes and peripheral artery disease (PAD), emphasizing its ability to improve walking ability and quality of life, independent of traditional metabolic improvements [8][19][20]. Group 1: Research Findings - Semaglutide shows a notable improvement in maximum walking distance (MWD) and pain-free walking distance (PFWD) for patients with symptomatic PAD [22]. - The STRIDE trial included 792 patients with symptomatic PAD, demonstrating that Semaglutide's efficacy is consistent across various patient characteristics, including diabetes duration, BMI, and blood sugar control [9][10][15]. - The study revealed that the improvement in walking ability is not significantly correlated with weight loss or blood sugar control, suggesting a novel mechanism of action for Semaglutide [17][18]. Group 2: Patient Characteristics and Efficacy - The efficacy of Semaglutide is consistent regardless of diabetes duration (less than 10 years vs. 10 years or more), BMI (less than 30 vs. 30 or more), and blood sugar levels (HbA1c less than 7% vs. 7% or more) [12][13][14]. - Patients using other glucose-lowering medications, such as SGLT2 inhibitors or insulin, also experienced significant improvements in walking ability [14] . Group 3: Safety and Clinical Implications - The safety profile of Semaglutide is comparable to that of the placebo group, with a balanced distribution of gastrointestinal side effects across subgroups [17][18]. - The findings suggest that Semaglutide could be a comprehensive treatment option for PAD in type 2 diabetes patients, enhancing lower limb circulation and functional capacity [20][21].